Zentek

Zentek owns a portfolio of patents around functionalized graphene oxide and derivatives, anchored by its zenGUARD virucidal coating. The compound is applied to air filtration media and has demonstrated rapid deactivation of SARS-CoV-2 variants, influenza, and other pathogens in lab and real-world HVAC settings (per peer-reviewed studies, 2022). The company also has patents pending for graphene-based corrosion coatings and battery anode materials.

Zentek generates revenue through a licensing-and-royalty model, relying on ISO-certified contract manufacturers for physical production. This lets the company avoid the capital cost of owning production lines while retaining the underlying patent rights. Revenue segments include PPE sales under Health Canada's interim order, HVAC filter licensing fees, and future royalties from life-science sublicenses (per the firm's financial disclosures).

The Zentek Surgical N95 respirator was first authorized by Health Canada as a Class I medical device under an Interim Order in 2022. That authorization has been renewed, most recently in September 2024, as the company works through the permanent registration pathway. No FDA clearance has been announced as of the latest available filings, though the company has indicated intent to pursue US regulatory pathways.

Yes, Zentek retains 100% ownership of the Albany Graphite Project in northern Ontario through its subsidiary Albany Graphite Corp. A bankable feasibility study was completed in 2015, but the asset is not core to current operations. The company has stated that any development will be tied to offtake or strategic partner interest, making it essentially an option on future graphite demand (per the firm, 2023).

Revenue streams include direct sale of zenGUARD-coated surgical masks into the Canadian healthcare market, licensing fees from HVAC filter manufacturers embedding zenGUARD into their products, and potential milestone payments from the Aptamir metabolic-disease therapeutic sublicense. The company has historically been pre-revenue or low-revenue, so allocation of capital — internal R&D, patent maintenance, and commercialization staff — remains the key metric over topline growth (per the firm's MD&A filings, 2023).

Zentek co-owns intellectual property with the University of Guelph arising from joint research on graphene-based applications. The university is a named co-assignee on several patent families. Zentek funds specific research programs at Guelph and has first rights to commercialize resulting inventions, creating an academic pipeline that feeds the firm's patent portfolio without requiring a large in-house basic-science team.

Zentek competes with other antimicrobial surface and filtration providers including Allied BioScience, Nanotera Group, and Promethean Particles, as well as large diversified players like 3M that integrate antimicrobial treatments into industrial filters. The firm's differentiator is the specific peer-reviewed mechanism of action — a non-leaching bound molecule that physically disrupts pathogen membranes rather than dissolving — which the company argues has superior durability and safety profile (per the firm's published white papers, 2023).